The use of intravenous immunoglobulin for treatment of dermatological conditions in Australia: A review

Australasian Journal of Dermatology

Volumn 51, Issue 4, 2010, Pages 227-237

  Smith, Saxon D ^a   Dennington, Peta M ^b   Cooper, Alan ^c  

^a SKIN AND CANCER FOUNDATION AUSTRALIA   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

bullous pemphigoid; cicatricial pemphigoid; dermatomyositis; epidermolysis bullosa acquisita; intravenous immunoglobulin; Kawasaki disease; mucous membrane pemphigoid; pemphigus foliaceus; pemphigus vulgaris; toxic epidermal necrolysis

Indexed keywords

IMMUNOGLOBULIN;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANOREXIA; ARTHRALGIA; ASEPTIC MENINGITIS; AUSTRALIA; BONE PAIN; BULLOUS PEMPHIGOID; CENTRAL RETINA VEIN OCCLUSION; CHILL; DERMATOMYOSITIS; DRUG MECHANISM; EPIDERMOLYSIS BULLOSA ACQUISITA; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUSHING; HEADACHE; HUMAN; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REVIEW; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STROKE; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS;

AUSTRALIA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PRACTICE GUIDELINES AS TOPIC; SKIN DISEASES;

EID: 78649261919     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2009.00578.x     Document Type: Review

References (59)

1. Jurisdictional Blood Committee, for and on Behalf of the Health Minister's Conference. Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia. Canberra: Commonwealth of Australia, 2007. Available from URL:. (Accessed 20 Mar 2008.)
2. National Blood Authority. National Blood Agreement between the Commonwealth of Australia and the States and Territories. Canberra: Commonwealth of Australia, 2003. Available from URL:. (Accessed 20 Mar 2008.)
3. Blood and Blood Products Committee. Review of the Use and Supply of Intravenous Immunoglobulins in Australia. A report by the Blood and Blood Products Committee (prepared under the auspice of the Australian Health Ministers' Advisory Council, Canberra). Canberra: Blood and Blood Products Committee, 2000.
4. Clynes R,. Protective mechanisms of IVIG. Curr. Opin. Immunol. 2007; 19: 646 - 51.
5. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinitypurified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 2002; 14: 1303 - 11.
6. Buchwald B, Ahangari R, Weishaupt A, et al., Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome [see comment]. Ann. Neurol. 2002; 51: 673 - 80.
7. Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 2003; 9: 431 - 8.
8. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490 - 3.
9. Sibéril S, Elluru S, Negi V, et al. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies. Transfus. Apher. Sci. 2007; 37: 103 - 7.
10. Thomas K, Ruetter A, Luger T,. Intravenous immunoglobulin therapy. In:, Wolverton SE, (ed.). Comprehensive Dermatologic Drug Therapy, 2nd edn. Philadelphia, PA: Saunders Elsevier, 2007; 459 - 69.
11. Sami N, Bhol KC, Ahmed AR,. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin. Immunol. 2002; 105: 192 - 8.
12. Negi V, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007; 27: 233 - 45.
13. Basta M, Fries LF, Frank MM,. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991; 77: 376 - 80.
14. Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004; 103: 465 - 72.
15. Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 2004; 113: 1328 - 33.
16. Ruiz de Souza V, Carreno MP, Kaveri SV, et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur. J. Immunol. 1995; 25: 1267 - 73.
17. Vassilev T, Yamamoto M, Aissaoui A, et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur. J. Immunol. 1999; 29: 2436 - 42.
18. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758 - 65.
19. Australian Red Cross Blood Service. Annual Report 2006-2007. Sydney: Australian Red Cross Blood Service, 2007.
20. Greenberg SA,. Inflammatory myopathies: evaluation and management. Semin. Neurol. 2008; 28: 241 - 9.
21. Wenzel J, Scheler M, Bieber T, et al. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br. J. Dermatol. 2005; 153: 462 - 3; author reply 2005; 153: 463-4
22. Sarkar K, Weinberg CR, Oddis C, et al. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum. 2005; 52: 2433 - 8.
23. Pachman LM, Lipton R, Ransey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005; 53: 166 - 72.
24. Iorizzo LJ, Jorizzo JL,. The treatment and prognosis of dermatomyositis: an updated review. J. Am. Acad. Dermatol. 2008; 59: 99 - 112.
25. Halbert AR,. Juvenile dermatomyositis. Australas. J. Dermatol. 1996; 37: 106 - 8.
26. Ming A, Wargon O,. Annular lesions in Kawasaki disease: a cause of confusion. Australas. J. Dermatol. 2008; 49: 207 - 12.
27. Leung D, Meissner H, Lucky A, et al. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 2, 7th edn. New York: McGraw-Hill, 2008; 168: 1626 - 33.
28. Burns JC, Glodé MP,. Kawasaki syndrome. Lancet 2004; 364: 533 - 44.
29. Pinna GS, Kafetzis DA, Tselkas OI, et al. Kawasaki disease: an overview. Curr. Opin. Infect. Dis. 2008; 21: 263 - 70.
30. Ashouri N, Takahashi M, Dorey F, et al. Risk factors for non-response to therapy in Kawasaki disease. J. Pediatr. 2008; 153: 365 - 8.
31. Hirata S, Nakamura Y, Yanagawa H,. Incidence of recurrent Kawasaki disease and related risk factors: for the results of nationwide surveys of Kawasaki disease in Japan. Acta Pediatr. 2001; 90: 40 - 4.
32. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst. Rev. 2003; (4): Art. No.: CD004000.
33. Kasperkiewicz M, Zillikens D,. The pathophysiology of bullous pemphigoid. Clin. Rev. Allergy Immunol. 2007; 33: 67 - 77.
34. Nousari HC, Anhalt GJ,. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667 - 72.
35. Stanley J,. Bullous pemphigoid. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 1, 7th edn. New York: McGraw-Hill, 2008; 54: 475 - 80.
36. Waisbourd-Zinman O, Ben-Amitai D, Cohen A, et al. Bullous pemphigoid in infancy: clinical and epidemiological characteristics. J. Am. Acad. Dermatol. 2008; 58: 41 - 8.
37. Ahmed AR, Dahl MV, for the Consensus Development Group. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch. Dermatol. 2003; 139: 1051 - 9.
38. Yancey K,. Cicatricial pemphigoid. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 1, 7th edn. New York: McGraw-Hill, 2008; 55: 481 - 5.
39. Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br. J. Dermatol. 1984; 110: 307 - 14.
40. Ahmed AR,. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin. Investig. Drugs 2004; 13: 1019 - 32.
41. Yeh SW, Usman AQ, Ahmed AR,. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow-up and influence of therapy. Clin. Immunol. 2004; 3: 268 - 72.
42. Bystryn JC, Jiao D, Natow S,. Treatment of pemphigus with intravenous immunoglobulin. J. Am. Acad. Dermatol. 2002; 47: 358 - 63.
43. Bystryn JC, Rudolph JL,. Pemphigus. Lancet 2005; 366: 61 - 73.
44. Wang W, Amagi M, Ishiko A,. Desmosome splitting is a primary ultrastructural change in the acantholysis of pemphigus. J. Dermatol. Sci. 2009; 54: 59 - 61.
45. Stanley J,. Pemphigus. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 1, 7th edn. New York: McGraw-Hill, 2008; 52: 459 - 68.
46. Loiseau P, Lecleach L, Prost C, et al. HLA class II polymorphism contributes to specify desmoglein-derived peptides in pemphigus vulgaris and pemphigus foliaceus. J. Autoimmun. 2000; 14: 67 - 73.
47. Sami N, Oureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch. Dermatol. 2002; 138: 1158 - 62.
48. Ahmed AR,. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int. Immunopharmacol. 2006; 6: 557 - 78.
49. Mentink LF, De Jong MC, Kloosterhuis GJ, et al. Coexistence of IgA antibodies to desmoglein 1 and 3 in pemphigus vulgaris, pemphigus folliaceus and paraneoplastic pemphigus. Br. J. Dermatol. 2007; 156: 635 - 41.
50. Bachot N, Revuz J, Roujeau JC,. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non-comparative study showing no benefit on mortality or progression. [comment]. Arch. Dermatol. 2003; 139: 85 - 6.
51. Campione E, Marulli GC, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm. Venereol. 2003; 83: 430 - 2.
52. Prins C, Vittorio C, Padilla RS, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicentre study. Dermatology 2003; 207: 96 - 9.
53. Trent J, Halem M, French LE, et al. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin. Cutan. Med. Surg. 2006; 25: 91 - 3.
54. Pereira FA, Mudgil AV, Rosmarin DM,. Toxic epidermal necrolysis. J. Am. Acad. Dermatol. 2007; 56: 181 - 200.
55. Gammon WR,. Epidermolysis bullosa acquisita. Semin. Dermatol. 1988; 7: 218 - 24.
56. Woodley D, Chen M,. Epidemolysis bullosa acquisita. In:, Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, (eds). Fitzpatrick's Dermatology in General Medicine, Vol. 1, 7th edn. New York: McGraw-Hill, 2008; 52: 494 - 500.
57. Bonilla FA,. Intravenous imunoglobulins: adverse reactions and management. J. Allergy Clin. Immunol. 2008; 122: 1238 - 9.
58. Aherns N, Hoflich C, Bombard S, et al. Immune tolerance induction in patients with IgA anaphylactoid reactions following long-term intravenous IgG treatment. Clin. Exp. Immunol. 2007; 151: 455 - 8.
59. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48: 1598 - 601.